Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 26, Issue 2, 1998, Pages 133-161

  Mesnil, Florence ^a   Mentré, France ^a   Dubruc, Catherine ^b   Thénot, Jean Paul ^b   Mallet, Alain ^a  

^a INSERM   (France)

^b SANOFI   (France)

Author keywords

Heteroscedastic variance; Mizolastine; NPML; Pharmacokinetics; Population analysis; Predictive distributions; Validation; Zero order absorption

Indexed keywords

MIZOLASTINE;

ADULT; ALLERGY; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CREATININE CLEARANCE; DATA ANALYSIS; DRUG ABSORPTION; DRUG DISPOSITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; VALIDATION PROCESS;

BENZIMIDAZOLES; HISTAMINE H1 ANTAGONISTS; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS;

EID: 0031765318     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020505722924     Document Type: Article

References (22)

1. J. L. Steimer, S. Vozeh, A. Racine-Poon, N. Holford, and R. O'Neill. The population approach: rationale, methods and applications in clinical pharmacology and drug development. In P. G. Welling and L. P. Balant (eds.), Handbook of Experimental Pharmacology. Vol. 110: Pharmacokinetics of Drugs, Springer Verlag, Berlin, 1994, pp. 405-451.
2. S. Vozeh, J. L. Steimer, M. Rowland, P. Morselli, F. Mentré, L. P. Balant, and L. Aarons. The use of population pharmacokinetics in drug development. Clin. Pharmacokin. 30:81-93 (1996).
3. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, J. H. Rodman, L. Sanathanan, J. J. Schentag, V. P. Shah, L. B. Sheiner, J. P. Skelly, D. R. Stanski, R. J. Temple, C. T. Viswanathan, J. Weissinger, and A. Yacobi. Conference report: Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51:465-473 (1992).
4. M. Davidian and D. M. Giltinan. Nonlinear Models for Repeated Measurement Data, Chapman and Hall, London, 1995.
5. S. Vozeh, P. O. Maitre, and D. R. Stanski. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J. Pharmacokin. Biopharm. 18:161-173 (1990).
6. F. Mesnil, C. Dubruc, F. Mentré, S. Huet, A. Mallet, and J. P. Thénot. Pharmacokinetic analysis of mizolastine in healthy volunteers after single oral and intravenous doses: Non-compartmental approach and compartmental modeling. J. Pharmacokin. Biopharm. 25:125-147 (1997).
7. A. Mallet. A maximum likelihood estimation method for random coefficient regression models. Biometrika 73:645-656 (1986).
8. N. Taright, F. Mentré, A. Mallet, and R. Jouvent. Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualisation of chronic dosing regimen using a new Bayesian approach. Ther. Drug Monit. 16:258-269 (1994).
9. M. Jerling, Y. Merlé, F. Mentré, and A. Mallet. Population pharmacokinetics of nortriptyline during monotheray and during concomitant treatment with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum likelihood method. Br. J. Clin. Pharmacol. 38:453-462 (1994).
10. F. Mentré and A. Mallet. Experiences with NPML: Application to dosage individualization of cyclosporine, gentamicin and zidovudine. In M. Rowland and L. Aarons (eds.), New strategies in Drug Development and Clinical Evaluation: The Population Approach, Commission of the European Communities, Luxembourg, 1992, pp. 75-90.
11. A. Gelman, J. B. Carlin, H. S. Stern, and D. B. Rubin. Bayesian Data Analysis, Chapman & Hall, London, 1995.
12. V. Ascalone, P. Guinebault, and A. Rouchouse. Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid liquid extraction, solid-phase extraction and column-switching techniques in combination with high-performance liquid chromatography. J. Chromatog. 619:275-284 (1993).
13. J. G. Wagner. Fundamentals of Clinical Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1975.
14. M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York, 1982.
15. R. D. Purves. Multiple solutions, illegal parameter values, local minima of the sum of squares, and anomalous parameter estimates in least-squares fitting of the two-compartment pharmacokinetic model with absorption. J. Pharmacokin. Biopharm. 24:79-101 (1996).
16. F. Mentré and A. Mallet. Handling covariates in population pharmacokinetics. Int. J. Biomed. Comput. 36:25-33 (1994).
17. D. W. Cockcroft and M. H. Gault. Prediction of creatinine clearance from serum creatinine. Nephron. 16:31-41 (1976).
18. J. D. Gibbons. Nonparametric Statistical Inference, McGraw-Hill, New York, 1971.
19. W. R. Gilks, S. Richardson, and D. J. Spiegelhalter. Markov Chain Monte Carlo in Practice, Chapman & Hall, London, 1996.
20. J. Wakefield and A. Racine-Poon. An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. Statist. Med. 14:971-986 (1995).
21. D. J. Roe. Comparison of population pharmacokinetic modeling methods using simulated data: results from the population modeling workgroup. Statist. Med. 16:1241-1262 (1997).
22. F. Mentré and M. E. Ebelin. Validation in population pharmacokinetic/pharmacodynamic analyses: Review of proposed approaches. In L. Aarons, L. P. Balant, M. Danhof, M. Gex-Fabry, U. A. Gundert-Remy, M. Karlsson, F. Mentré, P. L. Morselli, F. Rombout, M. Rowland, J. L. Steimer, and S. Vozeh (eds.), The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, European Commission, Geneva, 1997, pp. 147-160.